No data to show
XNAS
REVBW
Market cap1mUSD
Jun 20, Last price
0.01USD
1D
-0.83%
1Q
-6.30%
IPO
-95.42%
Name
Revelation Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-15.04b
L+12,505,543.06%
CFO
-18.32b
L+251,348.76%
Earnings
Aug 07, 2025
Profile
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 7,975,109 | 8,682 | 10,905 | |||
Unusual Expense (Income) | ||||||
NOPBT | (7,975,109) | (8,682) | (10,905) | |||
NOPBT Margin | ||||||
Operating Taxes | (35) | |||||
Tax Rate | ||||||
NOPAT | (7,975,109) | (8,682) | (10,870) | |||
Net income | (15,038,536) 12,505,543.06% | (120) -98.89% | (10,795) -9.95% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 5,417 | 14,025 | (3,191) | |||
BB yield | -685.13% | -408.37% | 2.97% | |||
| Debt | ||||||
Debt current | (2,911) | |||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 554 | |||||
Net debt | (6,499,018) | (11,992) | (8,164) | |||
| Cash flow | ||||||
Cash from operating activities | (18,321,276) | (7,286) | (11,219) | |||
CAPEX | (19) | (4) | ||||
Cash from investing activities | (19,171) | |||||
Cash from financing activities | 12,847,764 | 14,025 | 15,198 | |||
FCF | (8,039,886) | (10,693) | (9,006) | |||
| Balance | ||||||
Cash | 6,499,018 | 11,992 | 5,253 | |||
Long term investments | ||||||
Excess cash | 6,499,018 | 11,992 | 5,253 | |||
Stockholders' equity | (40,505,637) | (25,467) | (25,346) | |||
Invested Capital | 47,125,773 | 32,115 | 23,487 | |||
ROIC | ||||||
ROCE | 586.64% | |||||
| EV | ||||||
Common stock shares outstanding | 1,715 | 229 | 538 | |||
Price | 0.46 -96.93% | 15.02 -92.47% | 199.61 -98.14% | |||
Market cap | 791 -76.98% | 3,434 -96.80% | 107,487 -97.29% | |||
EV | (6,498,227) | (8,557) | 99,323 | |||
EBITDA | (7,947,186) | (8,657) | (10,879) | |||
EV/EBITDA | 0.82 | 0.99 | ||||
Interest | 35 | |||||
Interest/NOPBT | ||||||